Drug Trial Radar · NCT05995535
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
112
Actual
Start
Sep 1, 2024
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Conditions
- Opiate Withdrawal Syndrome
- Opioid Use
Interventions
LFX/PGBDrug
lofexidine tablets 0.18mg tabs pregabalin capsules 100mg and 25mg
LFX/PLA-PGBDrug
lofexidine tablets 0.18mg tabs pregabalin capsules 0mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjective Opioid Withdrawal Scale (SOWS) scoresTime frame: 10 days per subject, through study completion (N=150)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mountain Manor Treatment Center
Baltimore, Maryland
University of Pennsylvania, Treatment Research Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.